Ascendis Pharma (ASND) PT Lowered to $157 at TD Cowen
Tweet
Share
E-mailGet Alerts ASND Hot Sheet
Price: $222.92 -6.17%
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 6 | New: 31
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 6 | New: 31
Join SI Premium – FREE
TD Cowen analyst Yaron Werber lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $157.00 (from $175.00) while maintaining a Buy rating.
The analyst commented, "Skytrofa €26M revs missed our €73M/cons €77M impacted by €27M deductions from lower net selling price b/c of rebating. Price now stable w/€53M Q2 sales as real runrate into H2. FY24 guidance lowered to €220-€240M. Yorvipath €5M revs in line w/ our €5M/cons €6M. Full US launch expected in Q1:25 with $285k/yr list price. CNP Ph3 data in coming weeks (database locked), NDA filing pushed to Q1:25."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paramount Weighs Tapping Musk For Equity Investment - Semafor
- Scotiabank Reiterates Sector Outperform Rating on Hemlo Mining (HMMC:CN)
- UiPath Inc. (PATH) PT Lowered to $15 at UBS Following Investor Day
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Cowen & Co, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
